Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Christine Ambrose"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/84a97198f4cf4631a78e8d0a5b332b21
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
B cell lymphoma therapy has been transformed by CD19-targeting cellular therapeutics that induce high clinical response rates and impressive remissions in relapsed and refractory patients. However, approximately half of all patients who respond to CD
Externí odkaz:
https://doaj.org/article/26b6ad8375a14924a7d9b11e52588224
Publikováno v:
Cells, Vol 12, Iss 2, p 248 (2023)
The efficacy of CD19-specific CAR T cells in the treatment of leukemia/lymphoma relies, at least in part, on the unique properties of the particular CAR and the presence of healthy B cells that enhance the target cell lysis and cytokine secretion thr
Externí odkaz:
https://doaj.org/article/01fa912584b2484ab308bc29215d691d
Autor:
Christine Ambrose, Lihe Su, Lan Wu, Fay J Dufort, Thomas Sanford, Alyssa Birt, Benjamin J Hackel, Andreas Hombach, Hinrich Abken, Roy R Lobb, Paul D Rennert
Publikováno v:
PLoS ONE, Vol 16, Iss 3, p e0247701 (2021)
Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T cell expansion, persistence and fitness, and the ability to target tumor antigens safely. Here we address this constellation of critical attributes for successfu
Externí odkaz:
https://doaj.org/article/79b29881299c40a5997a27b51c18789e
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/29ca25875ed04214bdf8dfc827f09f7d
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d70fe18c7842ae98f9fdf0d1ddf8aae3
https://doi.org/10.1136/jitc-2022-sitc2022.0175
https://doi.org/10.1136/jitc-2022-sitc2022.0175
Autor:
Roy R. Lobb, Lan Wu, Christine Ambrose, Lihe Su, Paul Rennert, Thomas J Sanford, Fay J. Dufort, Alyssa Birt
Publikováno v:
Molecular Cancer Therapeutics. 20:2071-2081
Refractory acute myeloid leukemia (AML) remains an incurable malignancy despite the clinical use of novel targeted therapies, new antibody-based therapies, and cellular therapeutics. Here, we describe the preclinical development of a novel cell thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f5022f2671ddd6c6418c5a00c36673b
https://doi.org/10.1158/1535-7163.mct-20-1030
https://doi.org/10.1158/1535-7163.mct-20-1030
Autor:
Justin R. Klesmith, Roy R. Lobb, Alyssa Birt, Benjamin J. Hackel, Ian A. Schrack, Paul Rennert, Lan Wu, Christine Ambrose, Lihe Su, Fay J. Dufort
Publikováno v:
Molecular Pharmaceutics. 16:3544-3558
CD19-targeted chimeric antigen receptor (CAR) T-cells (CAR19s) show remarkable efficacy in the treatment of relapsed/refractory acute lymphocytic leukemia and Non-Hodgkin's lymphoma. However, the use of CAR T-cell therapy against CD19-negative hemato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db618f8499ca295995e1460dbc3b2e71
https://doi.org/10.1021/acs.molpharmaceut.9b00418
https://doi.org/10.1021/acs.molpharmaceut.9b00418
Abstract 2759: CAR-T engager proteins for the treatment of B cell cancers and acute myeloid leukemia
Publikováno v:
Cancer Research. 82:2759-2759
Chimeric Antigen Receptor T cells targeting malignancies expressing CD19 (CAR19) have been widely successful, with products approved to treat B cell lymphomas (NHL) and B cell leukemia. A major limitation of CAR19 therapy is the steep relapse rate wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef7538d2f12d1c868ee9f65e1e02b023
https://doi.org/10.1158/1538-7445.am2022-2759
https://doi.org/10.1158/1538-7445.am2022-2759
Autor:
Roy R. Lobb, Andreas Hombach, Hinrich Abken, Lan Wu, Alyssa Birt, Christine Ambrose, Lihe Su, Benjamin J. Hackel, Paul Rennert, Fay J. Dufort, Thomas J Sanford
Publikováno v:
PLoS ONE, Vol 16, Iss 3, p e0247701 (2021)
PLoS ONE
PLoS ONE
Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T cell expansion, persistence and fitness, and the ability to target tumor antigens safely. Here we address this constellation of critical attributes for successfu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0011fdf32a5a97cec62e959975fa4028
https://doi.org/10.1101/2020.03.25.007658
https://doi.org/10.1101/2020.03.25.007658
